New Drugs

FDA Approves Ontruzant (trastuzumab-dttb), a Biosimilar to Herceptin

6 years ago
by David Miller
1,044 Views
Written by David Miller

INCHEON, KOREA – January 21, 2019 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Ontruzant (trastuzumab-dttb), a biosimilar referencing Herceptin®i (trastuzumab), across all…Original Article

You may also like

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

Don`t Leave Yet!

Thank you!

[mwai_chat window="true" fullscreen="true"]